Hypera (OTCMKTS:HYPMY – Get Rating) and Myovant Sciences (NYSE:MYOV – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation. Risk & Volatility Hypera has a beta of 0.8, suggesting that […]